Dasatinib (BMS 354825)

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

Also Known As:

BMS 354825; (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; BMS-354825; BMS354825; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; Sprycel; 354825, BMS

Networked: 2197 relevant articles (270 outcomes, 417 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Cortes, Jorge: 42 articles (11/2020 - 06/2006)
2.	Kantarjian, Hagop: 37 articles (11/2020 - 06/2006)
3.	Hochhaus, Andreas: 37 articles (01/2020 - 03/2007)
4.	Cortes, Jorge E: 35 articles (12/2021 - 05/2008)
5.	Jabbour, Elias: 33 articles (05/2022 - 11/2006)
6.	Kantarjian, Hagop M: 33 articles (05/2022 - 02/2007)
7.	Breccia, Massimo: 24 articles (11/2021 - 01/2007)
8.	Shah, Neil P: 24 articles (01/2020 - 03/2005)
9.	Ravandi, Farhad: 23 articles (05/2022 - 08/2008)
10.	Kim, Dong-Wook: 23 articles (12/2021 - 04/2007)

Related Diseases

1.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/11/2012 - "Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia." 11/01/2011 - "Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features." 01/01/2022 - "[Successful child delivery in treatment-free remission of chronic myeloid leukemia after discontinuation of dasatinib]." 11/01/2010 - "We experienced a case of chronic myelogenous leukemia (CML) treated successfully with low-dose dasatinib (20 mg/day). " 01/01/2016 - "New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment."
2.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/01/2012 - "Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification." 03/01/2009 - "Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia." 10/01/2016 - "Long-term molecular remission in Philadelphia-positive acute lymphoblastic leukemia elderly patient after dasatinib discontinuation." 10/01/2023 - "PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity." 09/01/2023 - "Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review."
3.	Philadelphia Chromosome 12/01/2020 - "Patients with Philadelphia chromosome (Ph)-positive or Ph-like ALL with ABL-class fusion should be treated with dasatinib. " 09/10/2011 - "Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia." 05/01/2007 - "Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias." 06/01/2010 - "Achievement of complete donor-type chimerism and remission with dasatinib in Philadelphia chromosome-positive ALL relapsing after allogeneic transplantation." 07/01/2023 - "Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial."
4.	Neoplasms (Cancer) 06/15/2021 - "Obtained results showed that SMA-dasatinib is more potent against 4T1 TNBC tumor growth in vivo compared to free drug. " 11/01/2013 - "A significant reduction (P < 0.001) in tumor cell migration and invasion was also found following dasatinib treatment alone or in combination. " 01/01/2015 - "Although the combined use of Src inhibitor Dasatinib with other chemotherapeutic agents has shown superior efficacy for cancer treatment, the mechanisms that lead to enhanced sensitivity of Dasatinib are not completely understood. " 11/04/2023 - "All these findings suggest that fabricated DST-CH-FUC-NPs are promising biocompatible carriers for tumor-targeted delivery and enhanced efficacy of dasatinib." 01/01/2017 - "CRC cell lines and patient-derived tumor explant (PDX) models were used to investigate the efficacy of dasatinib. "
5.	Leukemia 01/01/2014 - "Furthermore, two recent studies showed dasatinib to be effective in inhibiting the in vitro growth of cells from leukemia patients with c-Cbl RING finger and linker domain mutations. " 10/01/2023 - "Finally, the induction of MHC II may potentiate immune memory by impairing leukemic engraftment in mice previously cured with dasatinib, after re-inoculation of leukemia cells. " 01/01/2014 - "Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI-resistant phenotype of human Ph+ ALL. " 01/01/2021 - "Based on this study, the use of a higher dosage of dasatinib (140 mg/d) is recommended in patients at high risk of CNS relapse or patients who need treatment for CNS leukemia. " 07/01/2013 - "Dasatinib 60 mg/m(2) and 80 mg/m(2) once-daily dosing were selected for phase II studies in children with Ph-positive leukemias."

Related Drugs and Biologics

1.	Imatinib Mesylate (Gleevec)
2.	nilotinib
3.	Tyrosine Kinase Inhibitors
4.	src-Family Kinases
5.	Quercetin
6.	bosutinib
7.	Phosphotransferases (Kinase)
8.	ponatinib
9.	amsonic acid (DAS)
10.	Dasatinib (BMS 354825)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Castration
4.	Drug Tapering
5.	Immunotherapy